Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Treatment of neurological injury with thymosin β4.
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Rituximab and multiple sclerosis.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.

Pages